The lineage-specific transcription factor (TF) MEF2C is often deregulated in leukemia. However, strategies to target this TF have yet to be identified. Here, we used a domain-focused CRISPR screen to reveal an essential role for LKB1 and its Salt-Inducible Kinase effectors (SIK3, in a partially redundant manner with SIK2) to maintain MEF2C function in acute myeloid leukemia (AML). A key phosphorylation substrate of SIK3 in this context is HDAC4, a repressive cofactor of MEF2C. Consequently, targeting of LKB1 or SIK3 diminishes histone acetylation at MEF2C-bound enhancers and deprives leukemia cells of the output of this essential TF. We also found that MEF2C-dependent leukemias are sensitive to on-target chemical inhibition of SIK activity....
Transcription factors form highly regulated and complex networks. In Acute Myeloid Leukaemia, driver...
Summary: Canonical NF-κB signaling is constitutively activated in acute myeloid leukemia (AML) stem ...
Acute myeloid leukemia (AML) is an aggressive disease for which only few targeted therapies are avai...
Lineage-defining transcription factors (TFs) are compelling targets for leukemia therapy, yet they a...
Acute myelogenous leukemia is driven by leukemic stem cells (LSCs) generated by mutations that confe...
Acute myeloid leukaemia (AML) is a heterogeneous disease characterized by transcriptional dysregulat...
Acute myelogenous leukemia is driven by leukemic stem cells (LSCs) generated by mutations that confe...
Acute myeloid leukaemia (AML) is a heterogeneous disease characterized by transcriptional dysregulat...
MYC oncoproteins regulate transcription of genes directing cell proliferation, metabolism and tumori...
Rearrangements that drive ectopic MEF2C expression have recurrently been found in patients with huma...
Ph+ acute lymphoblastic leukemia (ALL) is an aggressive disease characterized by a poor long-term su...
The blockade of cellular differentiation represents a hallmark of acute myeloid leukemia (AML), whic...
The blockade of cellular differentiation represents a hallmark of acute myeloid leukemia (AML), whic...
Targeting of general coactivators is an emerging strategy to interfere with oncogenic transcription ...
Acute Myeloid Leukemia (AML) is an aggressive hematological malignancy with abnormal progenitor self...
Transcription factors form highly regulated and complex networks. In Acute Myeloid Leukaemia, driver...
Summary: Canonical NF-κB signaling is constitutively activated in acute myeloid leukemia (AML) stem ...
Acute myeloid leukemia (AML) is an aggressive disease for which only few targeted therapies are avai...
Lineage-defining transcription factors (TFs) are compelling targets for leukemia therapy, yet they a...
Acute myelogenous leukemia is driven by leukemic stem cells (LSCs) generated by mutations that confe...
Acute myeloid leukaemia (AML) is a heterogeneous disease characterized by transcriptional dysregulat...
Acute myelogenous leukemia is driven by leukemic stem cells (LSCs) generated by mutations that confe...
Acute myeloid leukaemia (AML) is a heterogeneous disease characterized by transcriptional dysregulat...
MYC oncoproteins regulate transcription of genes directing cell proliferation, metabolism and tumori...
Rearrangements that drive ectopic MEF2C expression have recurrently been found in patients with huma...
Ph+ acute lymphoblastic leukemia (ALL) is an aggressive disease characterized by a poor long-term su...
The blockade of cellular differentiation represents a hallmark of acute myeloid leukemia (AML), whic...
The blockade of cellular differentiation represents a hallmark of acute myeloid leukemia (AML), whic...
Targeting of general coactivators is an emerging strategy to interfere with oncogenic transcription ...
Acute Myeloid Leukemia (AML) is an aggressive hematological malignancy with abnormal progenitor self...
Transcription factors form highly regulated and complex networks. In Acute Myeloid Leukaemia, driver...
Summary: Canonical NF-κB signaling is constitutively activated in acute myeloid leukemia (AML) stem ...
Acute myeloid leukemia (AML) is an aggressive disease for which only few targeted therapies are avai...